








**Figure 1.****A.****B.****C.****D.**

Figure 2

**A. Gel filtration chromatography****B. Affinity chromatography****C. Multimerization of HLA-DR4 with Streptavidin****BEST AVAILABLE COPY**

HLA-DR4 and HIV p24 (166-179)

Figure 3A





Figure 3B




**Figure 3C**

Figure 4




Figure 5




Figure 6




Figure 7






Figure 8

A.




B.

DR4 and HCV-1248




DR4 and HCV-1579



C.

DR4 and HCV-1248



DR4 and HCV-1579






Figure 9

## A. Before enrichment for DRB1\*0401 T tramer+ cells



## B. After enrichment for DRB1\*0401 Tetramer+ cells



## C. Functionality of 98A HCV-stimulated line






Figure 10

## A. Subject 01-40


## Before enrichment




## After enrichment





## Before enrichment



## After enrichment



## B. HCV/HIV-seronegative DRB1\*0401 control



## C. Subject 99-24






Figure 11




Figur 12

## A. 01-40 Fresh PBMC



## B. 01-40 NS3/4-stimulated line



## C. 98A NS3/4-stimulated line

